MX2022003075A - Métodos de tratamiento, usos y composiciones de rifabutina. - Google Patents
Métodos de tratamiento, usos y composiciones de rifabutina.Info
- Publication number
- MX2022003075A MX2022003075A MX2022003075A MX2022003075A MX2022003075A MX 2022003075 A MX2022003075 A MX 2022003075A MX 2022003075 A MX2022003075 A MX 2022003075A MX 2022003075 A MX2022003075 A MX 2022003075A MX 2022003075 A MX2022003075 A MX 2022003075A
- Authority
- MX
- Mexico
- Prior art keywords
- rifabutin
- solution
- formulation
- preparing
- acid
- Prior art date
Links
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 title abstract 11
- 229960000885 rifabutin Drugs 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- 239000002904 solvent Substances 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 239000000843 powder Substances 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una formulación de rifabutina producida a partir de un polvo de rifabutina en presencia de un ácido, agua y un disolvente adecuado para promover la disolución de la rifabutina; un método de preparación de una formulación de rifabutina, el método comprende: preparar una solución que comprende un disolvente, agua y un ácido; y agregar dicha solución a polvo de rifabutina, causando así la disolución de la rifabutina en la solución; un método de preparación de una formulación de rifabutina, el método comprende: preparar una solución que comprende agua y un ácido; y agregar dicha solución a una solución de rifabutina en un disolvente, produciendo así una formulación acuosa de rifabutina; un método de tratamiento de una infección bacteriana en un sujeto, el método comprende la administración de una cantidad terapéuticamente eficaz de rifabutina en una formulación inyectable o mediante inhalación.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899257P | 2019-09-12 | 2019-09-12 | |
| US201962902019P | 2019-09-18 | 2019-09-18 | |
| US201962941160P | 2019-11-27 | 2019-11-27 | |
| PCT/IB2020/000648 WO2021048612A1 (en) | 2019-09-12 | 2020-08-03 | Rifabutin treatment methods, uses, and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003075A true MX2022003075A (es) | 2022-07-11 |
Family
ID=72428294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003075A MX2022003075A (es) | 2019-09-12 | 2020-08-03 | Métodos de tratamiento, usos y composiciones de rifabutina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240000759A1 (es) |
| EP (1) | EP4027976A1 (es) |
| JP (1) | JP2022548858A (es) |
| KR (1) | KR20220103697A (es) |
| CN (1) | CN113015519A (es) |
| AU (1) | AU2020346414A1 (es) |
| BR (1) | BR112022004659A2 (es) |
| CA (1) | CA3154318A1 (es) |
| MX (1) | MX2022003075A (es) |
| WO (1) | WO2021048612A1 (es) |
| ZA (1) | ZA202203357B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230364065A1 (en) * | 2022-05-16 | 2023-11-16 | BioVersys AG | Antibiotic combination therapies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1775214A (zh) * | 2005-11-18 | 2006-05-24 | 武汉大学 | 利福喷丁、利福平、利福布丁或利福定注射剂及其制备方法 |
| MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| EA016410B1 (ru) * | 2010-11-13 | 2012-04-30 | Ооо "Нпк Наносистема" | Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты) |
| CN102178604B (zh) * | 2011-03-22 | 2014-03-05 | 中国人民解放军第三0九医院 | 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球 |
| EP3291798A4 (en) * | 2015-05-04 | 2019-01-16 | Gufic Biosciences Limited | LYOPHILIZED PHARMACEUTICAL FORMULATION OF RIFABUTIN AND PREPARATION METHOD THEREOF |
-
2020
- 2020-08-03 CN CN202080005144.XA patent/CN113015519A/zh active Pending
- 2020-08-03 BR BR112022004659A patent/BR112022004659A2/pt unknown
- 2020-08-03 CA CA3154318A patent/CA3154318A1/en active Pending
- 2020-08-03 JP JP2022516162A patent/JP2022548858A/ja active Pending
- 2020-08-03 WO PCT/IB2020/000648 patent/WO2021048612A1/en active Application Filing
- 2020-08-03 KR KR1020227012083A patent/KR20220103697A/ko unknown
- 2020-08-03 MX MX2022003075A patent/MX2022003075A/es unknown
- 2020-08-03 EP EP20768379.8A patent/EP4027976A1/en active Pending
- 2020-08-03 AU AU2020346414A patent/AU2020346414A1/en active Pending
-
2022
- 2022-03-22 ZA ZA2022/03357A patent/ZA202203357B/en unknown
-
2023
- 2023-09-12 US US18/465,226 patent/US20240000759A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020346414A1 (en) | 2022-04-14 |
| KR20220103697A (ko) | 2022-07-22 |
| ZA202203357B (en) | 2023-12-20 |
| US20240000759A1 (en) | 2024-01-04 |
| CA3154318A1 (en) | 2021-03-18 |
| EP4027976A1 (en) | 2022-07-20 |
| WO2021048612A1 (en) | 2021-03-18 |
| CN113015519A (zh) | 2021-06-22 |
| JP2022548858A (ja) | 2022-11-22 |
| BR112022004659A2 (pt) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411119B1 (ar) | تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها | |
| WO2019199861A3 (en) | Hemp extract for treatment of pain in animals | |
| NZ726366A (en) | Syk inhibitors | |
| MX2020005621A (es) | Derivados de acidos grasos para tratar la esteatohepatitis no alcoholica. | |
| UA114907C2 (uk) | Гетероциклільні сполуки як інгібітори mek | |
| TW201613885A (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| FI3258919T4 (fi) | Nasaalinen jauheformulaatio hypoglykemian hoitoon | |
| MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| EA032951B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
| SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
| JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
| FI3666258T3 (fi) | Menetelmä prader-willin oireyhtymän hoitamiseksi | |
| MX2017012958A (es) | Una composicion multilamelar acuosa para suministrar sustancia hidrofobicas. | |
| ZA202203357B (en) | Rifabutin treatment methods, uses, and compositions | |
| PH12015502128A1 (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| HRP20200031T1 (hr) | Uporaba cerebrolizina | |
| MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
| CN104434799A (zh) | 聚六亚甲基胍喷雾剂及其制备方法 | |
| NZ772538A (en) | Polymer nanoparticle composition for delivering virus, and preparation method therefor | |
| RU2020119597A (ru) | Композиция для лечения пациента с респираторным заболеванием, обусловленным хроническим воспалением, способ получения и применение указанной композиции | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2016014261A (es) | Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis. | |
| MX2011010783A (es) | Una crema medicinal hecha con crema de sulfato de framicetina y quitosano y un proceso para hacerla. |